Mehdi Farokhnia

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 29

Top Venues

Addiction (Abingdon, England)

ACS chemical neuroscience

Molecular psychiatry

Alcoholism, clinical and experimental research

National Institutes of Health

This page only lists publications with an associated author ORCID identifier.

Affiliation History

National Institutes of Health May 27 2014

United States

Postdoctoral Fellow :: NIAAA/NIDA

Roozbeh Psychiatric Hospital

Iran

Research Associate :: Psychiatric Research Center

Publications

Masoumeh Aminesmaeili, Mehdi Farokhnia, Ryoko Susukida, Lorenzo Leggio, Renee M Johnson, Rosa M Crum, Ramin Mojtabai
Reduced drug use as an alternative valid outcome in individuals with stimulant use disorders: Findings from 13 multisite randomized clinical trials. Addiction (Abingdon, England) 119 (5) (2024)
Masoumeh Aminesmaeili, Mehdi Farokhnia, Ryoko Susukida, Lorenzo Leggio, Renee M Johnson, Rosa M Crum, Ramin Mojtabai
Reduced drug use as an alternative valid outcome in individuals with stimulant use disorders: Findings from 13 multisite randomized clinical trials. Addiction (Abingdon, England) 119 (5) (2024)
Selim Boukabara, Mehdi Farokhnia, Lorenzo Leggio
Amylin in Alcohol Addiction: A Potential New Treatment Target or an Adjuvant to Other Treatments? ACS chemical neuroscience 15 (8) (2024)
Selim Boukabara, Mehdi Farokhnia, Lorenzo Leggio
Amylin in Alcohol Addiction: A Potential New Treatment Target or an Adjuvant to Other Treatments? ACS chemical neuroscience 15 (8) (2024)
Selim Boukabara, Mehdi Farokhnia, Lorenzo Leggio
Amylin in Alcohol Addiction: A Potential New Treatment Target or an Adjuvant to Other Treatments? ACS chemical neuroscience 15 (8) (2024)
Selim Boukabara, Mehdi Farokhnia, Lorenzo Leggio
Amylin in Alcohol Addiction: A Potential New Treatment Target or an Adjuvant to Other Treatments? ACS chemical neuroscience (2024)
Masoumeh Aminesmaeili, Mehdi Farokhnia, Ryoko Susukida, Lorenzo Leggio, Renee M Johnson, Rosa M Crum, Ramin Mojtabai
Reduced drug use as an alternative valid outcome in individuals with stimulant use disorders: Findings from 13 multisite randomized clinical trials. Addiction (Abingdon, England) (2024)
Masoumeh Aminesmaeili, Mehdi Farokhnia, Ryoko Susukida, Lorenzo Leggio, Renee M Johnson, Rosa M Crum, Ramin Mojtabai
Reduced drug use as an alternative valid outcome in individuals with stimulant use disorders: Findings from 13 multisite randomized clinical trials. Addiction (Abingdon, England) 119 (5) (2024)
Masoumeh Aminesmaeili, Mehdi Farokhnia, Ryoko Susukida, Lorenzo Leggio, Renee M Johnson, Rosa M Crum, Ramin Mojtabai
Reduced drug use as an alternative valid outcome in individuals with stimulant use disorders: Findings from 13 multisite randomized clinical trials. Addiction (Abingdon, England) 119 (5) (2024)
Masoumeh Aminesmaeili, Mehdi Farokhnia, Ryoko Susukida, Lorenzo Leggio, Renee M Johnson, Rosa M Crum, Ramin Mojtabai
Reduced drug use as an alternative valid outcome in individuals with stimulant use disorders: Findings from 13 multisite randomized clinical trials. Addiction (Abingdon, England) 119 (5) (2024)
Masoumeh Aminesmaeili, Mehdi Farokhnia, Ryoko Susukida, Lorenzo Leggio, Renee M Johnson, Rosa M Crum, Ramin Mojtabai
Reduced drug use as an alternative valid outcome in individuals with stimulant use disorders: Findings from 13 multisite randomized clinical trials. Addiction (Abingdon, England) 119 (5) (2024)
Ramin Mojtabai, Ryoko Susukida, Mehdi Farokhnia, Trang Quynh Nguyen, Kelly E Dunn, Masoumeh Aminesmaeili
Trajectories of craving in the course of pharmacotherapy trials for methamphetamine use disorder. Addiction (Abingdon, England) (2024)
Masoumeh Aminesmaeili, Mehdi Farokhnia, Ryoko Susukida, Lorenzo Leggio, Renee M Johnson, Rosa M Crum, Ramin Mojtabai
Reduced drug use as an alternative valid outcome in individuals with stimulant use disorders: Findings from 13 multisite randomized clinical trials. Addiction (Abingdon, England) 119 (5) (2024)
Sara L Deschaine, Morten A Hedegaard, Claire L Pince, Mehdi Farokhnia, Jacob E Moose, Ingrid A Stock, Sravani Adusumalli, Fatemeh Akhlaghi, James L Hougland, Agnieszka Sulima, Kenner C Rice, George F Koob, Leandro Vendruscolo, Birgitte Holst, Lorenzo Leggio
Initial pharmacological characterization of a major hydroxy metabolite of PF-5190457: inverse agonist activity of PF-6870961 at the ghrelin receptor . The Journal of pharmacology and experimental therapeutics (2023)
Madeline E Crozier, Mehdi Farokhnia, Susan Persky, Lorenzo Leggio, Brenda L Curtis
Relationship between self-stigma about alcohol dependence and severity of alcohol drinking and craving. BMJ mental health 26 (1) (2023)
Lorenzo Leggio, Christian S Hendershot, Mehdi Farokhnia, Anders Fink-Jensen, Mette Kruse Klausen, Joseph P Schacht, W Kyle Simmons
GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders. Nature medicine (2023)
Sara L Deschaine, Morten A Hedegaard, Claire L Pince, Mehdi Farokhnia, Jacob E Moose, Ingrid A Stock, Sravani Adusumalli, Fatemeh Akhlaghi, James L Hougland, Agnieszka Sulima, Kenner C Rice, George F Koob, Leandro Vendruscolo, Birgitte Holst, Lorenzo Leggio
Initial pharmacological characterization of a major hydroxy metabolite of PF-5190457: inverse agonist activity of PF-6870961 at the ghrelin receptor . The Journal of pharmacology and experimental therapeutics (2023)
András H Lékó, M Adrienne McGinn, Mehdi Farokhnia
The Mineralocorticoid Receptor: An Emerging Pharmacotherapeutic Target for Alcohol Use Disorder? ACS chemical neuroscience 13 (13) (2022)
Mehdi Farokhnia, Christopher T Rentsch, Vicky Choung, M Adrienne McGinn, Sophie K Elvig, Eliza A Douglass, Luis A Gonzalez, Jenna E Sanfilippo, Renata Cristina Nunes Marchette, Brendan J Tunstall, David A Fiellin, George F Koob, Amy C Justice, Lorenzo Leggio, Leandro F Vendruscolo
Spironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies. Molecular psychiatry (2022)
Mehdi Farokhnia, Brittney D Browning, Madeline E Crozier, Hui Sun, Fatemeh Akhlaghi, Lorenzo Leggio
The glucagon-like peptide-1 system is modulated by acute and chronic alcohol exposure: Findings from human laboratory experiments and a post-mortem brain study. Addiction biology 27 (5) (2022)
Kharbanda K Kusum, Mehdi Farokhnia, Sara L Deschaine, Raghav Bhargava, Marcela Rodriguez Flores, Carol A Casey, Anthony Peter Goldstone, Elisabeth Jerlhag, Lorenzo Leggio, Karuna Rasineni
Role of the ghrelin system in alcohol use disorder and alcohol-associated liver disease: A narrative review. Alcoholism, clinical and experimental research (2022)
Julia C Harris, Lorenzo Leggio, Mehdi Farokhnia
Blood Biomarkers of Alcohol Use: A Scoping Review. Current addiction reports 8 (4) (2021)
Vanessa A Palzes, Mehdi Farokhnia, Andrea H Kline-Simon, Joseph Elson, Stacy Sterling, Lorenzo Leggio, Constance Weisner, Felicia W Chi
Effectiveness of spironolactone dispensation in reducing weekly alcohol use: a retrospective high-dimensional propensity score-matched cohort study. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 46 (12) (2021)
Olli Kärkkäinen, Mehdi Farokhnia, Anton Klåvus, Seppo Auriola, Marko Lehtonen, Sara L Deschaine, Daria Piacentino, Kelly M Abshire, Shelley N Jackson, Lorenzo Leggio
Effect of intravenous ghrelin administration, combined with alcohol, on circulating metabolome in heavy drinking individuals with alcohol use disorder. Alcoholism, clinical and experimental research 45 (11) (2021)
Mehdi Farokhnia, Gray R McDiarmid, Matthew N Newmeyer, Vikas Munjal, Osama A Abulseoud, Marilyn A Huestis, Lorenzo Leggio
Effects of oral, smoked, and vaporized cannabis on endocrine pathways related to appetite and metabolism: a randomized, double-blind, placebo-controlled, human laboratory study. Translational psychiatry 10 (1) (2020)
Shervin Assari, Mehdi Farokhnia, Ritesh Mistry
Education Attainment and Alcohol Binge Drinking: Diminished Returns of Hispanics in Los Angeles. Behavioral sciences (Basel, Switzerland) 9 (1) (2019)
Shervin Assari, James Smith, Ritesh Mistry, Mehdi Farokhnia, Mohsen Bazargan
Substance Use among Economically Disadvantaged African American Older Adults; Objective and Subjective Socioeconomic Status. International journal of environmental research and public health 16 (10) (2019)
Mehdi Farokhnia, Sara L Deschaine, Armin Sadighi, Lisa A Farinelli, Mary R Lee, Fatemeh Akhlaghi, Lorenzo Leggio
A deeper insight into how GABA-B receptor agonism via baclofen may affect alcohol seeking and consumption: lessons learned from a human laboratory investigation. Molecular psychiatry 26 (2) (2018)
Mary R Lee, Jenica D Tapocik, Mwlod Ghareeb, Melanie L Schwandt, Alexandra A Dias, April N Le, Enoch Cobbina, Lisa A Farinelli, Sofia Bouhlal, Mehdi Farokhnia, Markus Heilig, Fatemeh Akhlaghi, Lorenzo Leggio
The novel ghrelin receptor inverse agonist PF-5190457 administered with alcohol: preclinical safety experiments and a phase 1b human laboratory study. Molecular psychiatry 25 (2) (2018)

Mehdi Farokhnia.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Mehdi Farokhnia